NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 07/16/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCRPRNewsWire • 07/16/26
NovoCure's Cancer Treatment Device Option Pax Gets European ApprovalZacks Investment Research • 07/01/26
Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic CancerBusiness Wire • 06/30/26
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 06/24/26
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool • 06/22/26
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law FirmBusiness Wire • 06/20/26
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)PRNewsWire • 06/19/26
Novocure Tumbles After Cancer-Fighting Medical Device Flops In Brain CancerInvestors Business Daily • 06/18/26
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed GlioblastomaBusiness Wire • 06/18/26
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC FilingThe Motley Fool • 06/09/26
International Markets and NovoCure (NVCR): A Deep Dive for InvestorsZacks Investment Research • 05/04/26
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break OutInvestors Business Daily • 04/30/26